mjb
4.8K posts

mjb
@AlbRt23
fooled by randomness as everybody

🚀 DeepSeek-V4 Preview is officially live & open-sourced! Welcome to the era of cost-effective 1M context length. 🔹 DeepSeek-V4-Pro: 1.6T total / 49B active params. Performance rivaling the world's top closed-source models. 🔹 DeepSeek-V4-Flash: 284B total / 13B active params. Your fast, efficient, and economical choice. Try it now at chat.deepseek.com via Expert Mode / Instant Mode. API is updated & available today! 📄 Tech Report: huggingface.co/deepseek-ai/De… 🤗 Open Weights: huggingface.co/collections/de… 1/n







The best Polymarket quant bot for copy-trading with 99.3% win rate. backtested on 72M Polymarket trades, his strategy printed +$820K across 28,000 predictions bot doesn’t gamble. It uses math, statistics & strict sizing rules to target high-probability edge how the algo works: 1. Mispricing formula from 72M trades, one pattern stands out: traders overpay for cheap contracts in the (0.1¢-50¢) range. most of the real edge shows up in (80¢-99¢) contracts, which is where the bot does most of its trading. • formula: δ = actual win rate - implied probability bot applies this to every trade to find the edge. // 2. Expected value calculation EV tells you whether a trade is worth taking, independent of what happens on any single bet. • formula: EV = (P win × Payout) - (P lose × Cost) bot calculates it to understand if the trade is worth the risk. // 3. Kelly Criterion sizing most powerful position sizing formulas ever used in gambling, trading, and prediction markets. It tells the bot what percentage of the portfolio to allocate to each position for long-term growth. • formula: f* = (p * b - q) / b Mispricing found → EV calculated → Kelly sizing applied → enter trade. profile: polymarket.com/0x751a2b86cab5… start copy-trading the bot with as little as $10 using Ares: t.me/AresProTrading… other Quant formulas behind its algo revealed in the article below ↓



Daraxonrasib is the "nasty drug" Ben Sasse is describing, and it may be the most important thing to happen to pancreatic cancer in a generation. RAS mutations drive more than 90% of pancreatic cancers. For decades the protein was considered undruggable. Daraxonrasib is the first in its class to directly target the active form of RAS, and in early trials second-line patients saw median progression-free survival of 8.8 months. The number most of these patients usually get is closer to two or three. The FDA granted it Breakthrough Therapy and Orphan Drug designation for a reason. The field is finally moving because we stopped chasing one answer and started attacking the biology that actually drives the disease. Ben is facing the most unforgiving diagnosis in oncology with extraordinary courage. Praying for him and his family.

Robert Wensley, a tech investor and startup commentator, recently criticized Sam Altman's leadership and past track record as a CEO.












